Phase II clinical trial of interleukin-2, interferon-alpha and tegafur uracil therapy for advanced renal cell cancer
Phase 2
Completed
- Conditions
- advanced renal cell cancer
- Registration Number
- JPRN-UMIN000002222
- Lead Sponsor
- Department of Urology Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1)uncontrolled DM (2)ischemic heart disease (3)allergic reaction to IL-2 and/or IFN-alpha (4)auto-immune disease (5)patients having Shou-Sai-Kotou (special herbal drug) and/or steroids (6)depression (7)Investigator determines as unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method anti-tumor response
- Secondary Outcome Measures
Name Time Method Time to progression, duration of response, overall survival, servival at home, performance status
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie IL-2, IFN-alpha, and tegafur uracil in JPRN-UMIN000002222 for advanced RCC treatment?
What is the efficacy comparison between JPRN-UMIN000002222's IL-2/IFN-alpha/tegafur uracil combo and tyrosine kinase inhibitors in advanced RCC?
What biomarkers predict response to IL-2, IFN-alpha, and tegafur uracil in JPRN-UMIN000002222 for advanced RCC?
What adverse events are associated with IL-2, IFN-alpha, and tegafur uracil in JPRN-UMIN000002222 and their management strategies?
What synergistic effects arise from combining IL-2, IFN-alpha, and fluoropyrimidines like tegafur uracil in advanced RCC treatment?